journal article·2017-04

Dual delivery of growth factors with coacervate-coated poly(lactic-co-glycolic acid) nanofiber improves neovascularization in a mouse skin flap model

Min Suk Lee, Taufiq Ahmad, Jinkyu Lee, Hassan K. Awada, Yadong Wang, Kyobum Kim, Heungsoo Shin, Hee Seok Yang

Biomaterials· Volume 124
Publisher page

Abstract

Random skin flaps are commonly used in plastic and reconstructive surgery for patients suffering from severe or large scale wounds or in facial reconstruction. However, skin flaps are sometimes susceptible to partial or complete necrosis at the distal parts of the flaps due to insufficient blood perfusion in the defected area. In order to improve neovascularization in skin flaps, we developed an exogenous growth factor (GF) delivery platform comprised of coacervate-coated poly(lactic-co-glycolic acid) (PLGA) nanofibers. We used a coacervate that is a self-assembled complex of poly(ethylene argininyl aspartate diglyceride) (PEAD) polycation, heparin, and cargo GFs (i.e., vascular endothelial growth factor (VEGF) and/or transforming growth factor beta 3 (TGF-β3)). The coacervate was coated onto a nanofibrous PLGA membrane for co-administration of dual GFs. In vitro proliferation of human dermal fibroblasts and endothelial tube formation using human umbilical vein endothelial cells indicated an enhanced bioactivity of released GFs when both VEGF and TGF-β3 were incorporated into coacervate-coated PLGA nanofibers (Coa-Dual NFs). Moreover, an in vivo study using a mouse skin flap model demonstrated that implantation of Coa-Dual NF reduced necrosis and enhanced blood perfusion in skin flap areas after 10 days, as compared to any single GF-loaded coacervate/PLGA fiber (Coa-Single NF) along with direct administration of the other GF onto the defect site. Moreover, Coa-Dual NFs exhibited a well-composed skin appendage and a significantly higher number of blood vessels. Based upon these results, we conclude that Coa-Dual NFs may stimulate cellular activity by enhancing the bioactivity of the released GF, leading to a synergetic effect of dual GFs for reducing necrosis in the random skin flaps. Therefore, Coa-Dual NFs could be a valuable drug delivery platform for a variety of potential clinical applications for skin tissue regeneration applications.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Reconstructive Surgery and Microvascular Techniques · Wound Healing and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (51)

Show source-provided references
1. The basic science of vascular biology: implications for the practicing surgeon10.1097/PRS.0b013e3181ef8ccf ↗
2. Enhanced random skin flap survival by sustained delivery of fibroblast growth factor 2 in rats10.1111/j.1445-2197.2012.06194.x ↗
3. Autologous transplantation of adipose-derived stem cells enhances skin graft survival and wound healing in diabetic rats10.1097/SAP.0b013e31826af01a ↗
4. Skin regeneration with fibroblast growth factor 2 released from heparin-conjugated fibrin10.1007/s10529-010-0492-5 ↗
5. Dual growth factor releasing multi-functional nanofibers for wound healing10.1016/j.actbio.2013.07.030 ↗
6. Tailored design of electrospun composite nanofibers with staged release of multiple angiogenic growth factors for chronic wound healing10.1016/j.actbio.2014.05.001 ↗
7. Improvement of venous flap survival by application of vascular endothelial growth factor in a rat model10.1097/01.sap.0000203998.37851.57 ↗
8. Combination of vascular endothelial growth factor-loaded microspheres and hyperbaric oxygen on random skin flap survival in rats10.3892/etm.2015.2620 ↗
9. Transforming growth factor-β3 promotes mesenchymal cell proliferation and angiogenesis mediated by the enhancement of cyclin D1, Flk-1, and CD31 gene expression during CL/Fr mouse lip fusion10.1002/bdra.20191 ↗
10. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring10.1242/jcs.108.3.985 ↗
11. Controlled delivery of heparin-binding EGF-like growth factor yields fast and comprehensive wound healing10.1016/j.jconrel.2012.11.004 ↗
12. Towards comprehensive cardiac repair and regeneration after myocardial infarction: aspects to consider and proteins to deliver10.1016/j.biomaterials.2015.12.025 ↗
13. Injectable fibroblast growth factor-2 coacervate for persistent angiogenesis10.1073/pnas.1110121108 ↗
14. Dual delivery of vascular endothelial growth factor and hepatocyte growth factor coacervate displays strong angiogenic effects10.1002/mabi.201300486 ↗
15. A [polycation: heparin] complex releases growth factors with enhanced bioactivity10.1016/j.jconrel.2010.11.025 ↗
16. Human progenitor cell recruitment via SDF-1α coacervate-laden PGS vascular grafts10.1016/j.biomaterials.2013.08.082 ↗
17. Poly (lactide-co-glycolide) porous scaffolds for tissue engineering and regenerative medicine10.1098/rsfs.2011.0123 ↗
18. Bioactive nanofibers: synergistic effects of nanotopography and chemical signaling on cell guidance10.1021/nl071182z ↗
19. Promotion of skin regeneration in diabetic rats by electrospun core-sheath fibers loaded with basic fibroblast growth factor10.1016/j.biomaterials.2011.02.042 ↗
20. Extracellular matrix-inspired BMP-2-delivering biodegradable fibrous particles for bone tissue engineering10.1039/C5TB01310K ↗
21. Human progenitor cell recruitment via SDF-1alpha coacervate-laden PGS vascular grafts10.1016/j.biomaterials.2013.08.082 ↗
22. Mussel-inspired immobilization of vascular endothelial growth factor (VEGF) for enhanced endothelialization of vascular grafts10.1021/bm300194b ↗
23. Osteochondral tissue regeneration using a bilayered composite hydrogel with modulating dual growth factor release kinetics in a rabbit model10.1016/j.jconrel.2013.03.013 ↗
24. Delivery of a cell patch of cocultured endothelial cells and smooth muscle cells using thermoresponsive hydrogels for enhanced angiogenesis10.1089/ten.tea.2015.0124 ↗
25. Botulinum toxin A and B raise blood flow and increase survival of critically ischemic skin flaps10.1016/j.jss.2013.04.004 ↗
26. Delivery of FGF-2 but not VEGF by encapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemia10.1038/sj.gt.3301436 ↗
27. Angiogenic response pattern during normal and impaired skin flap re-integration in mice: a comparative study10.1016/j.jcms.2014.06.004 ↗
28. Identification of the Fra-1 transcription factor in healing skin flaps transplants: a potential role as a negative regulator of VEGF release from keratinocytes10.1016/j.jcms.2011.07.001 ↗
29. A novel dermal substitute based on biofunctionalized electrospun PCL nanofibrous matrix10.1002/jbm.a.33143 ↗
30. Electrospun fibers immobilized with bone forming peptide-1 derived from BMP7 for guided bone regeneration10.1016/j.biomaterials.2013.03.051 ↗
31. Current approaches to electrospun nanofibers for tissue engineering10.1088/1748-6041/8/1/014102 ↗
32. Controlled dual delivery of fibroblast growth factor-2 and Interleukin-10 by heparin-based coacervate synergistically enhances ischemic heart repair10.1016/j.biomaterials.2015.08.050 ↗
33. Brush-like polycarbonates containing dopamine, cations, and PEG providing a broad-spectrum, antibacterial, and antifouling surface via one-step coating10.1002/adma.201402059 ↗
34. Polymeric system for dual growth factor delivery10.1038/nbt1101-1029 ↗
35. Growth factors in the treatment of diabetic foot ulcers10.1002/bjs.4019 ↗
36. TGF-β3 modulates the inflammatory environment and reduces scar formation following vocal fold mucosal injury in rats
37. A review of the prevention and treatment of hypertrophic scars: Part II. Experimental studies10.5455/aces.20120218125115 ↗
38. Transforming growth factor Beta 3 is required for excisional wound repair in vivo10.1371/journal.pone.0048040 ↗
39. Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring10.1111/j.1524-475X.2011.00711.x ↗
40. Prevention of buccal mucosa scarring with transforming growth factor β310.1002/lary.21759 ↗
41. Mechanisms of angiogenesis and arteriogenesis10.1038/74651 ↗
42. Transforming growth factor-β stimulates vascular endothelial growth factor production by folliculostellate pituitary cells10.1210/en.2002-220283 ↗
43. Lim · 2012
44. Conformation and self-association of human recombinant transforming growth factor-β3 in aqueous solutions10.1074/jbc.274.12.7699 ↗
45. Polycations and their biomedical applications10.1016/j.progpolymsci.2016.05.004 ↗
46. The interaction of the transforming growth factor-βs with heparin/heparan sulfate is isoform-specific10.1074/jbc.272.29.18000 ↗
47. Control growth factor release using a self-assembled [polycation∶ heparin] complex10.1371/journal.pone.0011017 ↗
48. Prevention and reduction of scarring in the skin by transforming growth factor beta 3 (TGFβ3): from laboratory discovery to clinical pharmaceutical10.1163/156856208784909345 ↗
49. Beneficial effects of aminoguanidine on skin flap survival in diabetic rats10.1155/2012/721256 ↗
50. Two-dimensional electrospun nanofibrous membranes for promoting random skin flap survival10.1039/C5RA23034A ↗
51. Coacervate delivery of HB-EGF accelerates healing of type 2 diabetic wounds10.1111/wrr.12319 ↗